Fidson Healthcare Limited (FIDSON.ng) Q32021 Interim Report

Fidson Healthcare Limited (FIDSON.ng) listed on the Nigerian Stock Exchange under the Health sector has released its 2021 interim results for the third quarter.

For more information about Fidson Healthcare Limited reports, abridged reports, interim earnings results and earnings presentations visit the Fidson Healthcare Limited company page on AfricanFinancials.

Indicative Share Trading Liquidity

The total indicative share trading liquidity for Fidson Healthcare Limited (FIDSON.ng) in the past 12 months, as of 1st November 2021, is US$1.24M (NGN496.87M). An average of US$103.7K (NGN41.41M) per month.

Fidson Healthcare Limited Interim Results for the Third Quarter Document

Company Profile

Fidson Healthcare Limited manufactures and sells pharmaceutical and nutraceutical products in Nigeria including over-the-counter, ethical and consumer products. The company produces various drug classes for antacid and ulcer care, anti-diabetic, anti-malaria, anti-diarrhea, anti-psychotic as well as osteo-care, pain relief, colds and flu, thrombo-prophylactics and cardio-vascular products. Fidson Healthcare Limited also produces a range of nutraceuticals (health) products. The company was incorporated in 1995 and its head office is in Shomolu, Nigeria. Fidson Healthcare Limited is listed on the Nigerian Stock Exchange